Co-Diagnostics

Co-Diagnostics reported a net loss of $1.46 per share in Q2 2026, beating analysts' estimate of -$3.00. Revenue was only $166,000, while operating expenses were cut by 23.2% and cash fell to $3.6 million, raising financing needs. Management reports progress on FDA submissions for influenza A/B and RSV, plans regulatory filings for tuberculosis, and expects to continue incurring operating losses in the near term. » Altro su de.investing.com

Co-Diagnostics hosted a delegation from joint-venture partner CoMira Diagnostics, which inspected automated production equipment and the future production line for PCR test kits in Utah. A technology transfer is planned so that CoMira can bring the molecular diagnostic platform and production capacity to Saudi Arabia and 18 other countries in the Middle East and North Africa. The partnership aims to scale local test production and also includes AI- and cloud-based monitoring features; the products are still under review by the FDA and other regulators. The company also reports significant financial strain: revenue fell 79% over the past twelve months to USD 720,000, market capitalization is USD 12.2 million, and while cash exceeds debt, cash burn is high. » Altro su de.investing.com

Co‑Diagnostics has signed a five‑year exclusive distribution agreement for the Co‑Dx PCR point‑of‑care platform in Mexico with its existing partner; the platform (including PCR Pro/Home and the app) is still under regulatory review. The partner has generated over USD 18 million in revenue since 2020 with Logix Smart tests and supported the market launch during the COVID‑19 pandemic. Financials: last‑12‑month revenue of USD 0.72 million with a market capitalization of USD 17.85 million; the stock fell 53% over six months but showed a recovery in the past month. Co‑Diagnostics has expanded product applications beyond COVID‑19 to tuberculosis, HPV, Mpox, H5N1 and an Ebola project. » Altro su de.investing.com

Co-Diagnostics announced it will develop a PCR assay for the Bundibugyo virus (BDBV) together with its Indian joint venture CoSara Diagnostics, after which the stock rose by around 40%. The goal is a configuration for both BDBV-specific and pan‑Ebola tests and to evaluate point-of-care and decentralized workflows. CoSara is intended to provide regional manufacturing capacity for rapid deployment in certain markets, subject to regulatory approvals. The Co-Dx PCR platform is still under review by the FDA and other authorities and is not commercially available. » Altro su de.investing.com

Joint venture CoMira Diagnostics has signed a lease for a roughly 14,400-square-foot production facility in Sudair Industrial City that, pending regulatory approvals, is intended to support manufacturing of the Co-Dx PCR platform and related products. The turnkey facility is expected to enable a faster transition to operational readiness and be part of a localization and expansion strategy for Saudi Arabia and the broader Middle East/North Africa region. Financials show significant headwinds: market capitalization about $6.95 million, revenue down 84% to $0.62 million over the last twelve months, but a gross margin of 64% and a current ratio of 3.87; analysts do not expect profitability this year. The stock has been highly volatile recently, rising 25% last week but remaining substantially down year to date. » Altro su de.investing.com